Lykos’s Knockback Could Be An Opportunity For Rivals

The group intends to appeal the US FDA’s rejection of its MDMA-based PTSD therapy, midomafetamine, but other psychedelics could advance in the meantime.    

WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)
• Source: Sarah Silbiger/Getty Images (Sarah Silbiger/Getty Images)

Lykos Therapeutics is not taking the rejection of midomafetamine lying down. The company said late on 9 August that the product, a version of the illicit drug MDMA for the treatment of post-traumatic stress disorder, had been knocked back by the US Food and Drug Administration. But Lykos plans to request a meeting with the agency so it can plead for a rethink.

Key Takeaways

  • Lykos Therapeutics’ approval application for midomafetamine was rejected by the FDA late last week.

Whether the FDA will reconsider its decision is far from clear. Certainly it has given in to appeals before –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip